⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MIST News
Milestone Pharmaceuticals Inc. Common Shares
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
businesswire.com
ATR
MIST
Lightspeed schließt neue Finanzierungsrunde in Höhe von über 9 Milliarden US-Dollar ab, um weltweit wegweisende Unternehmen zu unterstützen
businesswire.com
RBRK
NAVN
MIST
SNAP
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
globenewswire.com
MIST
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MIST
SAP Unveils EU AI Cloud: A Unified Vision for Europe's Sovereign AI and Cloud Future
prnewswire.com
SAP
COHR
MIST
OPEN
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
globenewswire.com
MIST
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MIST
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
globenewswire.com
MIST
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
globenewswire.com
MIST